The bone substudy of MA.27: Does bone make a difference?

The Lancet Oncology

Volumn 15, Issue 4, 2014, Pages 375-377

  Mathew, Aju ^a   Brufsky, Adam ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROEXEMESTANE; ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DRUG METABOLITE; ESTROGEN; EXEMESTANE; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITY; BREAST CANCER; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; NOTE; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; VITAMIN SUPPLEMENTATION;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; TRIAZOLES;

EID: 84897467094     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70050-6     Document Type: Note

References (9)

1. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
2. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
3. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
4. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
5. Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27-a randomized controlled phase III trial. J Clin Oncol 2013, 31:1398-1404.
6. Goss PE, Hershman DL, Cheung AM, et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol 2014, published online March 11. http://dx.doi.org/10.1016/S1470-2045(14)70035-X.
7. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007, 9:R52.
8. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405.
9. Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013, 18:353-361.